SCHEMBL5138002

SCHEMBL5138002

CCCCn1c(CN(Cc2ccc(C(=O)OC)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.51
TSHR P16473 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
ALDH1A1 P00352 4/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
MAPT P10636 2/20 0.40
AGTR1 P30556 1/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913103 0.95 C5AR1 (0.46) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL5134984 0.92 C5AR1 (0.54) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL5136174 0.89 C5AR1 (0.58) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL5134857 0.89 C5AR1 (0.60) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL647999 0.89 C5AR1 (0.62) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL5134636 0.88 AGTR1 (0.46) ALDH1A1KDM4EMAPTAGTR1
SCHEMBL5136237 0.88 C5AR1 (0.55) C5AR1TSHRPPARGPPARAGAA
SCHEMBL5135567 0.88 C5AR1 (0.56) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL5073883 0.88 C5AR1 (0.58) C5AR1TSHRPPARGPPARAALDH1A1
SCHEMBL650295 0.87 C5AR1 (0.48) C5AR1TSHRPPARGPPARAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed